Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
The Pharma Data
APRIL 11, 2023
Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program. Based on these data, a first-in-human trial with BAY 2965501 in patients with advanced solid tumors was initiated and is currently enrolling patients.
Let's personalize your content